ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0109

Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?

Eileen Rife1, Emejuaiwe Nkechinyere2 and Jose Leon de la Rocha3, 1Louisiana State University, Metairie, LA, 2Department of Veterans Affairs, New Orleans, LA, 3Louisiana State University, Auburn, AL

Meeting: ACR Convergence 2020

Keywords: Dual energy x-ray absorptiometry (DEXA), glucocorticoids, osteoporosis, practice guidelines, prevention

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Osteoporosis & Metabolic Bone Disease Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Descriptive study designed to assess compliance to evidence-based practice guidelines for the prevention of Glucocorticoid-Induced Osteoporosis (GIOP).

Methods: We queried the electronic database of the Department of Veterans Affairs Hospital in New Orleans and collected data on all veterans who filled systemic glucocorticoid (GC) prescriptions during a 2-year study period (January 1, 2016 – December 31, 2017). Data was collected on GC dosage and duration of therapy – with long term GC therapy defined as continuous treatment for ≥3 months (90 days).  Data was also collected on demographics, specialty of the ordering prescriber, bone mineral density (BMD) testing, prescriptions for anti-osteoporotic therapy, and prescriptions for Vitamin D and/or Calcium supplementation. The recommendations followed were in accordance with the American College of Rheumatology, American Geriatrics Society, Institute of Medicine, and National Osteoporosis Foundation guidelines.

Results: During our study period, a total of 1,962 separate GC prescriptions were filled. Of those, 1,051 unique patients were identified. A total of 206 patients were prescribed GC for ≥90 days during the study window and they comprised our study population. Patients were predominately male (97%); 51% self-identified as Caucasian, and 46% as African American. A majority (68%) of prescriptions were for less than 10mg prednisolone-equivalent doses.  Most prescriptions (63% n=130) were for >7.5mg prednisolone-equivalent doses for greater than 90 days.  Primary care providers were the main prescribers of long-term GC (51%, n=105), followed by rheumatologists (24%, n=49). BMD testing was performed in 20% of patients (n=42). Of those tested, 14% (n=6) were found to have osteoporosis and 21% (n=9) had osteopenia. Approximately half of our study population (52%) were prescribed Vitamin D supplementation with 80% prescribed the guideline-recommended dose. Twenty-six percent of patients were prescribed supplemental Calcium, with 44% prescribed the guideline-recommended dose. Fewer than 10% of the patients taking greater than 7.5mg for ≥3 months (and meeting ACR treatment guidelines) were on primary prophylaxis with anti-osteoporotic therapy.

Conclusion: Our findings are overall worsethan previously published data. GIOP remains an under recognized and undertreated condition despite updated evidence-based practice guidelines. Bone mineral density screening rates remain low, as do Calcium/Vitamin D supplementation and primary prophylaxis with anti-osteoporotic therapy.


Disclosure: E. Rife, None; E. Nkechinyere, None; J. Leon de la Rocha, None.

To cite this abstract in AMA style:

Rife E, Nkechinyere E, Leon de la Rocha J. Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/glucocorticoid-induced-osteoporosis-are-we-practicing-prevention/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/glucocorticoid-induced-osteoporosis-are-we-practicing-prevention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology